Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved therapies ...

When connected to another device, it can even model how the bone marrow communicates with other organs, like the lungs, to protect them from infections and other potentially life-threatening ...

What makes the lungs such a tempting place for cancer cells ... Translation is the process that uses our genetic code as a blueprint to make proteins in cells. A change in the translational ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Blueprint is closely tracking Lilly and filed pralsetinib, formerly known as BLU-667, with the FDA in RET-positive non-small cell lung cancer in early April. It then filed for approval in ...